Amica Mutual Insurance Co. continued to hold its position in Mylan (NASDAQ:MYL) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 67,751 shares of the company’s stock at the end of the first quarter. Amica Mutual Insurance Co.’s holdings in Mylan were worth $2,642,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MYL. Strs Ohio raised its position in Mylan by 1.6% in the third quarter. Strs Ohio now owns 272,694 shares of the company’s stock worth $10,395,000 after buying an additional 4,399 shares during the period. Great West Life Assurance Co. Can raised its position in Mylan by 7.1% in the third quarter. Great West Life Assurance Co. Can now owns 326,046 shares of the company’s stock worth $12,412,000 after buying an additional 21,521 shares during the period. Texas Permanent School Fund raised its position in Mylan by 2.5% in the third quarter. Texas Permanent School Fund now owns 141,672 shares of the company’s stock worth $5,401,000 after buying an additional 3,474 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Mylan by 13.0% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 70,471 shares of the company’s stock worth $2,686,000 after buying an additional 8,094 shares during the period. Finally, Chicago Equity Partners LLC raised its position in Mylan by 38.1% in the third quarter. Chicago Equity Partners LLC now owns 55,390 shares of the company’s stock worth $2,111,000 after buying an additional 15,290 shares during the period. Hedge funds and other institutional investors own 60.89% of the company’s stock.
Shares of Mylan (NASDAQ:MYL) traded down 0.29% during trading on Friday, reaching $37.90. The company had a trading volume of 5,568,919 shares. The stock has a 50 day moving average of $38.91 and a 200 day moving average of $38.68. The stock has a market capitalization of $20.30 billion, a price-to-earnings ratio of 41.20 and a beta of 1.14. Mylan has a 52-week low of $33.60 and a 52-week high of $50.40.
Mylan (NASDAQ:MYL) last released its quarterly earnings data on Wednesday, March 1st. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.15. The firm had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.18 billion. Mylan had a net margin of 2.50% and a return on equity of 22.04%. During the same quarter in the prior year, the business earned $1.22 earnings per share. Equities research analysts forecast that Mylan will post $5.28 EPS for the current year.
A number of research firms have weighed in on MYL. Vetr cut Mylan from a “strong-buy” rating to a “buy” rating and set a $44.68 price target on the stock. in a research note on Monday, February 6th. Zacks Investment Research upgraded Mylan from a “sell” rating to a “hold” rating in a research note on Monday, February 27th. Mizuho restated a “buy” rating and issued a $47.00 price target on shares of Mylan in a research note on Tuesday, February 28th. Royal Bank of Canada set a $48.00 price target on Mylan and gave the company a “hold” rating in a research note on Thursday, March 2nd. Finally, Guggenheim restated a “neutral” rating on shares of Mylan in a research note on Friday, March 3rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $51.85.
In related news, major shareholder Laboratories Abbott sold 44,000,000 shares of the stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $41.60, for a total transaction of $1,830,400,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.71% of the stock is owned by corporate insiders.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).